Show simple item record

dc.contributor.authorYılmaz, Öznur
dc.contributor.authorÖZTAY, FÜSÜN
dc.date.accessioned2021-03-03T15:56:30Z
dc.date.available2021-03-03T15:56:30Z
dc.identifier.citationÖZTAY F., Yılmaz Ö., "Dasatinib for use in the treatment, regression or decelerating the progress of fibrotic lung diseases", Diğer, ss.1-6, 2016
dc.identifier.othervv_1032021
dc.identifier.otherav_418cad44-4159-486d-9258-9655d3470085
dc.identifier.urihttp://hdl.handle.net/20.500.12627/47807
dc.identifier.urihttp://google.com/patents/WO2016159917A1?cl=en&hl=tr
dc.description.abstractThe present invention relates to the use of dasatinib or its pharmaceutically acceptable salts thereof as a potential pharmaceutical agent, more preferably anti-proliferative or anti-fibrotic agent in fibrotic lung diseases, in particular idiopathic pulmoner fibrosis (IPF) disease.
dc.language.isoeng
dc.subjectTek Midelilerin Beslenmesi
dc.subjectZootekni ve Hayvan Besleme
dc.subjectYemler ve Hayvan Besleme
dc.subjectZiraat
dc.subjectTarımsal Bilimler
dc.subjectBiyoloji ve Biyokimya
dc.subjectYaşam Bilimleri (LIFE)
dc.titleDasatinib for use in the treatment, regression or decelerating the progress of fibrotic lung diseases
dc.typeDiğer Yayınlar
dc.contributor.departmentDiğer Kurumlar , ,
dc.contributor.firstauthorID659163


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record